Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study

B. Sigurgeirsson; L. Kircik; O. Nemoto; I. Mikazans; S. Haemmerle; H. J. Thurston; C. Papavassilis; H. B. Richards

doi:10.1111/jdv.12343

Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study

B. Sigurgeirsson, L. Kircik, O. Nemoto, I. Mikazans, S. Haemmerle, H. J. Thurston, C. Papavassilis, H. B. Richards

Department of Dermatology and Venereology

Research output: Contribution to journal › Letter › peer-review

18 Citations (Scopus)

Original language	English
Pages (from-to)	1127-1129
Number of pages	3
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	28
Issue number	8
DOIs	https://doi.org/10.1111/jdv.12343
Publication status	Published - Aug 2014

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdv.12343

https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.12343

Cite this

Sigurgeirsson, B., Kircik, L., Nemoto, O., Mikazans, I., Haemmerle, S., Thurston, H. J., Papavassilis, C., & Richards, H. B. (2014). Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. Journal of the European Academy of Dermatology and Venereology, 28(8), 1127-1129. https://doi.org/10.1111/jdv.12343

Sigurgeirsson, B. ; Kircik, L. ; Nemoto, O. et al. / Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet : Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. In: Journal of the European Academy of Dermatology and Venereology. 2014 ; Vol. 28, No. 8. pp. 1127-1129.

@article{2ad22199487a499186f98f32e57d67bf,

title = "Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study",

author = "B. Sigurgeirsson and L. Kircik and O. Nemoto and I. Mikazans and S. Haemmerle and Thurston, {H. J.} and C. Papavassilis and Richards, {H. B.}",

year = "2014",

month = aug,

doi = "10.1111/jdv.12343",

language = "English",

volume = "28",

pages = "1127--1129",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell",

number = "8",

}

Sigurgeirsson, B, Kircik, L, Nemoto, O, Mikazans, I, Haemmerle, S, Thurston, HJ, Papavassilis, C & Richards, HB 2014, 'Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study', Journal of the European Academy of Dermatology and Venereology, vol. 28, no. 8, pp. 1127-1129. https://doi.org/10.1111/jdv.12343

Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. / Sigurgeirsson, B.; Kircik, L.; Nemoto, O. et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 28, No. 8, 08.2014, p. 1127-1129.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet

T2 - Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study

AU - Sigurgeirsson, B.

AU - Kircik, L.

AU - Nemoto, O.

AU - Mikazans, I.

AU - Haemmerle, S.

AU - Thurston, H. J.

AU - Papavassilis, C.

AU - Richards, H. B.

PY - 2014/8

Y1 - 2014/8

UR - http://www.scopus.com/inward/record.url?scp=84905862282&partnerID=8YFLogxK

U2 - 10.1111/jdv.12343

DO - 10.1111/jdv.12343

M3 - Letter

C2 - 24330415

AN - SCOPUS:84905862282

SN - 0926-9959

VL - 28

SP - 1127

EP - 1129

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 8

ER -

Sigurgeirsson B, Kircik L, Nemoto O, Mikazans I, Haemmerle S, Thurston HJ et al. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. Journal of the European Academy of Dermatology and Venereology. 2014 Aug;28(8):1127-1129. doi: 10.1111/jdv.12343

Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Cite this